Related Experiment Video
Updated: Jan 30, 2026
Acute Myocardial Infarction in Rats
Published on: February 16, 2011
Early Cardiac Mitochondrial Molecular and Functional Responses to Acute Anthracycline Treatment in Wistar Rats
Gonçalo C Pereira1,2, Susana P Pereira1,3, Francisco B Pereira4,5
1CNC - Center for Neuroscience and Cell Biology, University of Coimbra, UC-Biotech, Cantanhede, Portugal.
Abstract:
Doxorubicin (DOX) is an anticancer drug widely used to treat human and nonhuman tumors but the late and persistent cardio-toxicity reduces the therapeutic utility of the drug. The full mechanism(s) of DOX-induced acute, subchronic and delayed toxicity, which has a preponderant mitochondrial component, remains unclear; therefore, it is clinically relevant to identify early markers to identify patients who are predisposed to DOX-related cardiovascular toxicity. To address this, Wistar rats (16 weeks old) were treated with a single DOX dose (20 mg/kg, i.p.); then, mRNA, protein levels and functional analysis of mitochondrial endpoints were assessed 24 h later in the heart, liver, and kidney. Using an exploratory data analysis, we observed cardiac-specific alterations after DOX treatment for mitochondrial complexes III, IV, and preferentially for complex I. Conversely, the same analysis revealed complex II alterations are associated with DOX response in the liver and kidney. Interestingly, H2O2 production by the mitochondrial respiratory chain as well as loss of calcium-loading capacity, markers of subchronic toxicity, were not reliable indicators of acute DOX cardiotoxicity in this animal model. By using sequential principal component analysis and feature correlation analysis, we demonstrated for the first time alterations in sets of transcripts and proteins, but not functional measurements, that might serve as potential early acute markers of cardiac-specific mitochondrial toxicity, contributing to explain the trajectory of DOX cardiac toxicity and to develop novel interventions to minimize DOX cardiac liabilities.
Insights
Doxorubicin (DOX) chemotherapy causes heart damage. This study identified early molecular markers in rat hearts, not functional tests, that may predict DOX cardiotoxicity, aiding in patient risk assessment.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Doxorubicin (DOX) is a vital anticancer agent, but its clinical use is limited by dose-dependent cardiotoxicity.
- The precise mechanisms underlying DOX-induced acute and delayed cardiac toxicity, particularly its mitochondrial component, remain incompletely understood.
- Identifying early predictive biomarkers for DOX cardiotoxicity is crucial for patient stratification and risk management.
Purpose of the Study:
- To investigate early molecular changes in mitochondria following acute Doxorubicin administration in a rat model.
- To identify potential early biomarkers of cardiac-specific mitochondrial toxicity induced by Doxorubicin.
- To differentiate cardiac-specific DOX effects from those in other organs like the liver and kidney.
Main Methods:
- Wistar rats received a single intraperitoneal dose of Doxorubicin (20 mg/kg).
- Cardiac, liver, and kidney tissues were analyzed 24 hours post-treatment for mRNA and protein levels of mitochondrial components.
- Mitochondrial functional assays (H2O2 production, calcium-loading capacity) and advanced statistical analyses (PCA, feature correlation) were employed.
Main Results:
- Doxorubicin treatment induced cardiac-specific alterations in mitochondrial complexes I, III, and IV at the transcript and protein levels.
- Mitochondrial complex II alterations were observed in the liver and kidney, distinct from cardiac effects.
- Early functional markers like H2O2 production and calcium-loading capacity did not reliably predict acute cardiotoxicity in this model.
Conclusions:
- Sets of transcript and protein alterations, rather than functional measurements, may serve as early acute markers for cardiac-specific mitochondrial toxicity.
- These findings provide novel insights into the early trajectory of Doxorubicin cardiac toxicity.
- The identified molecular signatures could facilitate the development of strategies to mitigate Doxorubicin-induced cardiac liabilities.
Related Concept Videos
02:59Animal Mitochondrial Genetics
02:19Export of Mitochondrial and Chloroplast Genes
02:16Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes
02:35Molecular Orbital Theory I
03:51Molecular Orbital Theory II
03:07Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy